Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 21;6(10):4491-519.
doi: 10.3390/nu6104491.

The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment

Affiliations
Review

The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment

Andrea Dueregger et al. Nutrients. .

Abstract

Prostate cancer (PCa), the most commonly diagnosed cancer and second leading cause of male cancer death in Western societies, is typically androgen-dependent, a characteristic that underlies the rationale of androgen deprivation therapy (ADT). Approximately 90% of patients initially respond to ADT strategies, however many experience side effects including hot flashes, cardiotoxicity, metabolic and musculoskeletal alterations. This review summarizes pre-clinical and clinical studies investigating the ability of dietary supplements to alleviate adverse effects arising from ADT. In particular, we focus on herbal compounds, phytoestrogens, selenium (Se), fatty acids (FA), calcium, and Vitamins D and E. Indeed, there is some evidence that calcium and Vitamin D can prevent the development of osteoporosis during ADT. On the other hand, caution should be taken with the antioxidants Se and Vitamin E until the basis underlying their respective association with type 2 diabetes mellitus and PCa tumor development has been clarified. However, many other promising supplements have not yet been subjected large-scale clinical trials making it difficult to assess their efficacy. Given the demographic trend of increased PCa diagnoses and dependence on ADT as a major therapeutic strategy, further studies are required to objectively evaluate these supplements as adjuvant for PCa patients receiving ADT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of action of androgen deprivation therapy (ADT) for blockage of the hypothalamus-pituary axis.
Figure 2
Figure 2
Side effects associated with androgen deprivation therapy (ADT).

References

    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. Cancer J. Clin. 2012;62:10–29. doi: 10.3322/caac.20138. - DOI - PubMed
    1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. Cancer J. Clin. 2014;64:9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004;25:276–308. doi: 10.1210/er.2002-0032. - DOI - PubMed
    1. Denis L.J. The role of active treatment in early prostate cancer. Radiother. Oncol. 2000;57:251–258. doi: 10.1016/S0167-8140(00)00284-X. - DOI - PubMed
    1. Lieberman R. Androgen deprivation therapy for prostate cancer chemoprevention: Current status and future directions for agent development. Urology. 2001;58:83–90. doi: 10.1016/S0090-4295(01)01247-X. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources